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Background: Patients having chronic schizophrenia with frequent relapses and hospitalizations represent a great
challenge, both clinically and financially. Risperidone long-acting injection (RIS-LAI) has been the main LAI atypical
antipsychotic treatment in Greece. Paliperidone palmitate (PP-LAI) has recently been approved. It is dosed monthly,
as opposed to biweekly for RIS-LAI, but such advantages have not yet been analysed in terms of economic
evaluation.
Purpose: To compare costs and outcomes of PP-LAI versus RIS-LAI in Greece.
Methods: A cost-utility analysis was performed using a previously validated decision tree to model clinical
pathways and costs over 1 year for stable patients started on either medication. Rates were taken from the
literature. A local expert panel provided feedback on treatment patterns. All direct costs incurred by the national
healthcare system were obtained from the literature and standard price lists; all were inflated to 2011 costs. Patient
outcomes analyzed included average days with stable disease, numbers of hospitalizations, emergency room visits,
and quality-adjusted life-years (QALYs).
Results: The total annual healthcare cost with PP-LAI was €3529; patients experienced 325 days in remission and
0.840 QALY; 28% were hospitalized and 15% received emergency room treatment. With RIS-LAI, the cost was €3695,
patients experienced 318.6 days in remission and 0.815 QALY; 33% were hospitalized and 17% received emergency
room treatment. Thus, PP-LAI dominated RIS-LAI. Results were generally robust in sensitivity analyses with PP-LAI
dominating in 74.6% of simulations. Results were sensitive to the price of PP-LAI.
Conclusions: PP-LAI appears to be a cost-effective option for treating chronic schizophrenia in Greece compared
with RIS-LAI since it results in savings to the health care system along with better patient outcomes.
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GreeceIntroduction
Glazer and Ereshefsky [1] were the first to conduct a
pharmacoeconomic analysis on patients affected with
so-called “revolving door” schizophrenia. The label was
adopted to describe persons suffering from chronic dis-
ease with multiple relapses, frequent hospitalizations,
and problems with adherence to prescribed medications.
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reproduction in any medium, provided the orpreventing them from living a normal life. They are also
responsible for increased expenditures for healthcare, so-
cial services, and the justice system [2].
Antipsychotic drugs can help many revolving door
patients to remain in a stable condition; however, a major
problem for them is adherence to these prescribed drugs
[1,3]. The adherence of patients with schizophrenia is
reduced over time. In fact, it has been demonstrated that
partial adherence (i.e. missing 25-50% of doses) can reach
50% in 1 year and 75% in 2 years [4]. An important ad-
vance in enhancing adherence has been the depot form of
these drugs, also referred to as long-acting injectablesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cause of their prolonged effect and consequent prevention
of much of the intentional and non-intentional non-
adherence that results in treatment failures and hospitali-
zations [3]. The clinically meaningful superiority of depot
medication compared to oral antipsychotic drugs in out-
patients with schizophrenia has also been confirmed by
the findings of a recent meta-analysis which demonstrated
that depot formulations significantly reduced relapses
from an average of 33.2% to 21.5% [5].
A further advance has been the development of atyp-
ical antipsychotics. They have advantages over the trad-
itional drugs in that they improve both the positive and
negative symptoms of the disease [6]. A depot form of
atypical antipsychotic was not available until 2002, the
first of which was risperidone (RIS-LAI) [7,8]. In a re-
view of the clinical research, Möller concluded that RIS-
LAI displayed clinical efficacy and a reasonable degree
of tolerability [8]. Moreover, based on the results of a re-
cent multi-centre cohort study across 15 French regions
that accounted for 77.6% of the French population in
2005, RIS-LAI use compared to all other LAIs and first
or second generation per os antipsychotics was asso-
ciated with a 34% reduced rate of hospitalization [9]. A
clinical disadvantage is that, although clinically effective,
it must be administered every two weeks, usually by a
specially trained psychiatric nurse or physician [10].
More recently, paliperidone palmitate (PP-LAI) has
been developed and approved by the European Medicines
Agency [11]. Among the other advantages that it shares
with existing drugs, this new product has an added advan-
tage in that it may be administered monthly [12]. PP-LAI
is already marketed in several European markets, most
often at a higher acquisition price than RIS-LAI.
Although the clinical use of PP-LAI has been investi-
gated in a number of randomized controlled trials [13-17],
few economic evaluations have yet been conducted. A
search of the international peer reviewed literature
revealed one study from the USA that included PP-LAI
[18]. However, that study did not use data inputs gener-
ated by PP-LAI, but rather they used data from RIS-LAI
studies and assumed the two drugs to be exactly equal.
Considering differences in dosing regimens, such assump-
tions and associated cost outcomes may not be valid. Sev-
eral pharmacoeconomic studies have compared RIS-LAI
with other drugs, mainly oral atypicals and traditional
depots. In his review of those studies, Haycox found that
RIS-LAI was the dominant strategy in all eight different
countries, using different analytical models [19].
In Greece, a single pharmacoeconomic study by Gei-
tona and associates [20] was published which focused on
paliperidone extended release oral tablets. That study
demonstrated that paliperidone was cost-effective over
all other oral drugs tested, including risperidone,olanzapine, quetiapine, ziprasidone and aripiprazole.
Paliperidone had the lowest overall cost and the highest
number of days with stable disease. No other similar
studies from Greece could be located.
Given that PP-LAI has a higher acquisition price than
RIS-LAI and taking into consideration the scarcity of
resources health care systems are faced with, economic
evaluation of new technologies is important for decision
making purposes. The aim of this paper is to compare
costs and outcomes of PP-LAI versus RIS-LAI for the




Unlike a clinical trial, patients are not recruited into this
research. Rather, a decision model was used to repre-
sent the average patient being treated using standard
approaches.
Therefore, it is necessary to define the population to
whom results would apply. The population of interest
consisted of patients having chronic schizophrenia with
multiple relapses, frequent hospitalizations, and pro-
blems with adherence to prescribed medications. At ini-
tiation of the analysis, all patients were stable and
treated as outpatients with maintenance doses of their
LAIs. For the purposes of this analysis, comorbidities
were not considered even though they are common in
this population [21].
Drugs of interest
The primary drug of interest was PP-LAI, which was
compared against RIS-LAI. Long term use of PP-LAI
has been investigated in a number of randomized con-
trolled trials [13-17]; one of these trials involved a com-
parison with RIS-LAI [15]. As previously mentioned, the
European Medicines Agency has approved PP-LAI for
monthly dosing [12], while RIS-LAI is administered
every two weeks [10]. It should be noted that at the time
of this analysis PP-LAI was not marketed in Greece and
there was no local clinical experience.
Model and base case
Data were modelled for one year using a previously vali-
dated decision tree [22], which appears in Figure 1,
adapted for use in Greece. An expert panel was recruited
and interviewed to provide clinical input describing pat-
terns of patient management in this country. To enter
the model, an average patient with chronic relapsing
schizophrenia must be an outpatient with stable disease
treated with either PP-LAI or RIS-LAI. The patient can
be either adherent or non-adherent, according to pub-
lished rates and expert opinion. Patients can remain
stable or can relapse, with treatment either in the
Figure 1 Decision tree model used for the pharmacoeconomic analysis.
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who cannot tolerate the primary drug or refuse to take it
are switched to olanzapine oral tablets. In the event of a
subsequent failure on that drug, clozapine oral tablets
are prescribed [23,24].Table 1 Clinical inputs into the model and sources of informa
Rate RIS-LAI Source
Probabilities
Adherence 0.823 Olivares [26]
Adherent, stable disease 0.763 Calculation [1 - (ER exacerbation
rate + hospitalization rate)]
Adherent, exacerbation
requiring ER visit
0.071 Ratio of ER vists: hospitalizations
Ascher-Svanum [28]
Adherent, hospitalized 0.166 Olivares [29]
Non-adherent, stable 0.140 Kane [30]
Non-adherent,
exacerbation




0.586 Assumption; PP rate adjusted based o
calculations by Mehnert & Diels [27]
Dosing
Maintenance dose 40.3 mg
biweekly
Fleischhacker [15], Kissling [32], Lee [3
Lindenmayer [34], Olivares [29]
Dose after relapse 50 mg
biweekly*
Risperdal ConstaW Approved Summar





Risperdal ConstaW Approved Summar
Product Characteristics [10] maximum
Clozapine maintenance




Clozapine maximum dose 750 mg
daily
Simonsen[23], Wahlbeck [24]
ER emergency room, PP-LAI paliperidone palmitate long-acting injection (XeplionW)
*A slightly higher average dose of 58.2 mg biweekly was used in clinical trials in pa
Eerdekens[36]; however, they used a dose of 75 mg mg in some patients, which is
maximum.Clinical inputs
Given the challenge of collecting valid local data for
populating the model, which has also been identified in
the relevant literature [25], data on resource utilisation,
frequency and duration of relapses were mainlytion
PP-LAI Source
0.872 RIS rate adjusted via Mehnert [27]
0.803 Calculation [1 - (ER exacerbation
rate + hospitalization rate)]
0.059 Ratio of ER vists: hospitalizations
Ascher-Svanum [28]
0.138 Gopal [14], Hough [13]
0.148 Hough [13]
0.299 Calculation [1 - (Stable
rate + hospitalization rate)]
n 0.553 Morken [31]
3], 69.3 mg monthly Gopal[14], Fleischhacker [15]
y of
dose
84.9 mg monthly Gopal [35], Pandina [36], Hough [16],
Nasrallah [37], Pandina [38]
y of
dose
150 mg week 1,
100 mg week 2, then
84.9 mg every 4 weeks
XeplionW Product monograph [12],
Hough [13]
; RIS-LAI risperidone microspheres long-acting injection (Risperdal ConstaW)
tients with acute eacerbations of schizophrenia by Kane [5], Chue [35], and
not commercially available and which exceeds the now-recommended
Table 2 Cost inputs into the economic model (2011€)
Resource Item Unit Cost Source
Drugs paliperidone palmitate mg € 2.90 calculation*
risperidone microspheres mg € 2.52 calculation†
olanzapine tablets mg € 0.27 calculation†
clozapine tablets mg € 0.0023 calculation†
Medical visit/injection 1 visit € 10.12 Geitona [20], Urdahl [42]
Hospital emergency room 1 visit € 50.00 Syriopoulou [43]
hospital bed acute care 21 days € 146 for the first 21 days DRG tariffs{
hospital bed acute care 1 day € 45.00/day after 21 days DRG tariffs{
day hospital 1 day € 36.86 Geitona [20], Urdahl [42]
*Based on available EU prices in the 22 countries used for reference pricing in Greece at the end of September 2011.
†Based on hospital prices published in Price Bulletin 4/8/2011 and IMS Greece market shares July 2011.
{Calculation based on officially published Ministry of Health Diagnosis Related Group (DRG) tariffs, Government Gazette B 1702/1-8-2011.
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psychiatrists. Other clinical rates and associated data
inputs were determined from the literature (Table 1)
[10,12-16,23,24,26-40]. The doses of drugs actually
administered in long term trials of these drugs were
used, rather than the Daily Defined Doses (DDDs) as
published by the World Health Organization. DDDs rep-
resent the average dose for the drug when used in its
most common indication, which does not represent our
target population [41]. In the present analysis, the re-
search hypothesis is focused on frequently relapsing
patients, necessitating hospitalization and intensive
intervention. Therefore, DDDs may underestimate the
doses used in the real world when treating these
patients, whereas doses from the clinical trials could be
considered as better proxy for real world dosing.
Cost inputs
Costs were considered from the perspective of the Na-
tional Health Service of Greece. We included only direct
costs of care while indirect costs, such as time lost from
work, were excluded (Table 2) [20,42,43]. We did not
apply discounting because the analysis had a time hori-
zon of one year. Prices were taken from official bulletins
or from the literature, then inflated to 2011 Euros using
the Consumer Price Index for Greece [44].
Analysis and outputs
For each drug, we calculated the average cost per patient
treated. Patient outcomes analyzed included average days
with stable disease, numbers of hospitalizations, emer-
gency room visits, and quality-adjusted life-years (QALYs).
To derive utilities (i.e., the quality weights) for this quality
adjustment, preference based estimates were obtained
from the literature [45-49]. Each of the three primary
health states (i.e., stable disease, exacerbation requiring
emergency room treatment, and hospitalization) were
weighted using the average of the reported utility scores.QALYs were then estimated for each drug by multiplying
the amount of time in each health state by the quality
value assigned to that health state. Therefore, a cost-utility
analysis was conducted, which involves calculating the in-
cremental treatment cost per QALY as the pharmacoeco-
nomic outcome. In addition, a cost-effectiveness analysis
was performed in order to assess other important clinical
outcomes, such as the number of stable and relapse days
as well as rates of hospitalisation and emergency room
visits.
Several sensitivity analyses were performed to deter-
mine if alterations in clinical or cost inputs would influ-
ence outputs. One-way sensitivity analyses were done to
identify break-even points, that is, what the values would
have to be in order for PP-LAI to cost more than RIS-
LAI. We conducted one-way sensitivity analyses on im-
portant parameters such as rates of adherence,
hospitalization, and emergency room visits as well as
drug acquisition costs. Finally, all variables were varied
over plausible ranges in a probabilistic sensitivity ana-
lysis (also called a Monte Carlo simulation) with 10,000
iterations. That analysis reproduces results for a large
group of patients and gives a projection of what average
costs and outcomes would be.Results
Cost analysis
The total direct cost to treat one patient over the year
was calculated for each drug, as presented in Table 3.
Included in those calculations were drugs, medical care
(visits) and hospital care, based on the units presented in
Table 2. The overall cost to treat patients with PP-LAI
was lower than with RIS-LAI by €166, despite having a
higher acquisition cost. In the case of PP-LAI, drugs
accounted for the largest proportion of the total costs
(61%), while hospitalization comprised 30% and medical
care the remaining 9%. Costs for RIS-LAI had a similar
Table 3 Cost-utility analysis results from comparing paliperidone and risperidone long acting injections for chronic
schizophrenia in Greece
Drug Total cost per patient* Total QALYs per patient Incremental cost per patient Incremental QALYs per patient Economic conclusion
PP-LAI €3,529 0.840 -€166 0.025 dominant
RIS-LAI €3,695 0.815 dominated
LAI long acting injectable, PP paliperidone palmitate, RIS risperidone microspheres, QALY quality adjusted life years.
*All costs are in 2011 Euros.
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pital care and 11% medical care.
Cost-utility analysis
The primary pharmacoeconomic analysis was cost-utility,
which simultaneously compares costs and QALYs. Along
with costs, Table 3 also lists the numbers of QALYs asso-
ciated with the use of each drug. In the base case, patients
treated with PP-LAI have a higher QALY score, meaning
that they experience more time with a higher quality of
life. Because PP-LAI has a lower cost and a greater num-
ber of QALYs, it is considered dominant over RIS-LAI.
That means it is the preferred treatment and should be
adopted, providing it is affordable.
Cost-effectiveness analysis
Table 4 displays the other clinical outcomes of interest,
which were numbers of stable and relapse days as well
as rates of hospitalization and emergency room visits.
Patients receiving PP-LAI experienced more days with
stable disease and fewer days in relapse. Fewer of them
visited the emergency room or were hospitalized. Since
PP-LAI has a lower cost and all outcomes were superior,
it dominated RIS-LAI in all of these scenarios. These
observations confirm that PP-LAI is the preferred strategy
to RIS-LAI.
Sensitivity analyses
To test the robustness of the model and its results, an
array of different sensitivity analyses were conducted. In
one-way sensitivity analyses, the model was insensitive
to variations in rates of hospitalization or emergency
room visits. That means results would not change and
favour RIS-LAI regardless of how many patients were
hospitalized or treated in the emergency room. As well,
for cost equality between drugs, the adherence rate for







PP-LAI 325.0 39.0 0.1
RIS-LAI 318.6 45.4 0.1
LAI long acting injectable, PP paliperidone palmitate, RIS risperidone microspheres,
*Total and incremental costs per patient are onsidered as in Table 3.RIS-LAI remained the same), which is not a reasonable
scenario.
In the Monte Carlo synthesis, 74.6% of the 10,000
simulations favoured PP-LAI. Figure 2 depicts the scat-
terplot of costs versus QALYs. All points below the hori-
zontal line labelled €0.0 represent lower costs for PP-
LAI and points to the right of the vertical line represent
greater quality of life for patients treated with PP-LAI,
as opposed to RIS-LAI.
Discussion
This pharmacoeconomic analysis aims to assess the clin-
ical and economic value of PP-LAI as a new treatment
option in schizophrenia and to support decision making
with respect to efficient allocation of resources within
the Greek health care setting. Decision analytic model-
ling was used to estimate and compare the costs and
effects of PP-LAI and RIS-LAI in outpatients with
chronic schizophrenia within a 1 year time horizon. In
this analysis, PP-LAI was the dominant treatment option
as it was associated with improved outcomes and a
lower average total treatment cost per year.
Overall, the cost of treatment was slightly lower for
the healthcare system when PP-LAI was used, despite a
higher acquisition cost. It appears that the price of the
drug is more than offset by savings accrued from less
frequent drug administration and higher adherence
rates, as used in our model.
The only other pharmacoeconomic analysis of schizo-
phrenia in Greece was that of Geitona and colleagues
who investigated paliperidone extended release tablets
[20]. Their calculated cost was just over €7,030 for both
paliperidone and risperidone oral tablets, with drugs
comprising €1,541 (21.9%) and €1,293 (18.4%) of the
totals, respectively. Our overall costs were lower, pos-
sibly reflecting the different patient population, i.e.. the








QALY quality adjusted life years.
Figure 2 Cost-effectiveness plot of the Incremental Cost Utility Ratio (X-axis = difference in QALYs, Y-axis = difference in costs in 2011
Euros.
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ted to the improved efficacy (i.e., via higher adherence
rates) and the reduced hospitalisation rates associated
with LAI formulations [50]. In our analysis, drugs
accounted for 61% and 56% of the total costs, respect-
ively, which reflect the higher acquisition costs of the
LAIs. Nonetheless, the final results were somewhat simi-
lar, with paliperidone dominating risperidone.
Limitations
While reviewing these results it is important to keep in
mind the potential limitations of this analysis. An appar-
ent limitation was the fact that local expert panel was
used for estimating specific input parameters to the
model, namely, those associated with resource utilization
in the Greek setting. Although this approach has been
followed before in other similar studies [19,20], it could
lead to potentially biased estimates. However, in the light
of the absence of real life resource utilization data the
expert panel could give a picture of the actual clinical
setting. Furthermore, in our model we did not include
the costs for treating adverse events. One reason was
that the drugs are closely related, with paliperidone
being a metabolite of risperidone [12]. Therefore, one
might expect the efficacy and safety profiles to be quite
similar. In fact, that assumption of equal side effect rates
was made in a recently published pharmacoeconomic
analysis in the USA that included both of these drugs[18]. Geitona and associates [20] did include some of
these events, but found that the associated cost was triv-
ial and had no impact on the model. Similar results have
been reported by Vera-Llonch and coworkers [51], who
estimated the monthly cost associated with side effect
management for risperidone and olanzapine. It should
be noted that our model captured the discontinuation
and switching rates, which are also attributed to adverse
events.Health policy implications
Efficient resource allocation has become a priority for
policy makers across Europe and in Greece in particular.
That applies to healthcare as well and to the manage-
ment of patients with chronic schizophrenia. Health eco-
nomic studies could provide significant tools for well
documented and rational decision making given the
scarcity of resources and the increasing control on
health care and pharmaceutical expenditure. Pharmacoe-
conomic analyses, like the one presented, give quantita-
tive estimates of the costs of care and identify the
preferred choices for drug treatment. In the case of PP-
LAI, its adoption would actually lead to savings for the
system, since the overall cost of care would decrease.
Both clinicians and managers within the system need to
become aware of these analyses and use them to the ad-
vantage of both themselves and patients.
Einarson et al. Annals of General Psychiatry 2012, 11:18 Page 7 of 8
http://www.annals-general-psychiatry.com/content/11/1/18Conclusions
In Greece, PP-LAI should be preferred to RIS-LAI for
treating patients with chronic relapsing schizophrenia be-
cause it has both clinical and economic advantages. The
analysis showed that PP-LAI has a lower overall cost to
the health care system and greater clinical benefits in
terms of QALYs, days in remission, hospitalizations, and
visits to the emergency room for exacerbations of schizo-
phrenia. If adopted, it should result in net savings to the
system of €166 per patient treated per year, along with
better quality patient care. These findings could be further
validated when PP-LAI becomes commercially available in
Greece and clinical experience is accumulated. Future re-
search efforts, could focus on conducting economic eva-
luations based on “real-life” data with respect to clinical
outcomes and resource utilization in the local setting, pro-
viding this way deeper analysis of the cost-effectiveness of
PP-LAI.
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